Pivotal Role of TARC, a CC Chemokine, in Bacteria-induced Fulminant Hepatic Failure in Mice

Hiroyuki Yoneyama,* Akihisa Harada,* Toshio Imai,* Masataka Baba,§ Osamu Yoshie,† Yi Zhang,* Hidemitsu Higashi,* Masako Murali,* Hitoshi Asakura,* and Kouji Matsushima†

*Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan; †Third Department of Internal Medicine, Niigata University School of Medicine, Niigata 951, Japan; §Shionogi Institute for Medical Science, Osaka 566, Japan; and ‡Department of Bacteriology, Kinki University School of Medicine, Osaka 589, Japan

Abstract

Thymus and activation-regulated chemokine (TARC) is a recently identified lymphocyte-directed CC chemokine which specifically chemoattracts T helper type 2 CD4+ T cells in human. To establish the pathophysiological roles of TARC in vivo, we investigated whether a monoclonal antibody (mAb) against TARC could inhibit the induction of hepatic lesions in murine model using Propionibacterium acnes and lipopolysaccharide (LPS). P. acnes–induced intrahepatic granuloma formation in the priming phase is essential to the subsequent liver injury elicited by a low dose of LPS. The priming phase appears to be dominated by Th1 type immune responses determined by the profile of chemokine and chemokine receptor expression. TARC was selectively produced by granuloma-forming cells, and CC chemokine receptor 4 (CCR4)-expressing CD4+ T cells migrated into the liver after LPS administration. In vivo injection of anti-TARC mAb just before LPS administration protected the mice from acute lethal liver damage, which was accompanied by a significant reduction of both CCR4 mRNA expression and IL-4 production by liver-infiltrating CD4+ T cells. Moreover, both TNF-α and Fas ligand expressions in the liver were decreased by anti-TARC treatment. These results suggest that recruitment of IL-4–producing CCR4+ CD4+ T cells by granuloma-derived TARC into the liver parenchyma may be a key cause of massive liver injury after systemic LPS administration. (J. Clin. Investig. 1998. 102: 1933–1941.) Key words: chemokines • Th1 cells • Th2 cells • hepatitis • granuloma

Introduction

The microenvironment in areas of inflammation may provide optimal conditions for the emigration of lymphocytes from the blood (1, 2). Chemokines, a family of low molecular weight proteins that induce specific types of leukocyte chemotaxis, play essential roles in regulating the extravasation and tissue accumulation of lymphocytes during immune and inflammatory responses (1, 3–6). Recent investigations have revealed the existence of a large number of novel lymphocyte-directed chemokines (3, 7–10). Among these CC chemokines, thymus and activation-regulated chemokine (TARC) is the first CC chemokine to be shown to selectively chemoattract T lymphocytes (8). TARC was subsequently identified to be a specific ligand for CC chemokine receptor 4 (CCR4)-expressing cells (9), and induces chemotaxis of T cells, especially of the Th2 type CD4+ human T lymphocytes (3, 11, 12, and Imai, T., N. Gray, K. Matsushima, and O. Yoshie, manuscript submitted for publication). However, the in vivo pathophysiological roles of TARC remain to be elucidated.

Fulminant hepatic failure (FHF) is a clinical syndrome characterized by sudden and severe impairment of liver function. Histopathological examination reveals diffuse intraparenchymal infiltration by inflammatory cells with massive multilobular necrosis. Intraparenchymal infiltrates are composed predominantly of T lymphocytes, and Fas ligand (FasL) expression is found in areas with lymphocytic infiltration (13). Heat-killed Propionibacterium acnes followed by a subsequent challenge with a low dose of LPS induces acute and massive liver injury, mimicking FHF (14). This liver injury model can be pathophysiologically classified into two phases: the early priming phase induced by P. acnes, and the late eliciting phase induced by LPS. At the priming phase, mononuclear cells infiltrate into the liver lobes, leading to a granuloma formation. At the eliciting phase, inflammatory infiltrates are further increased, resulting in massive hepatocellular damage around granulomas due to necrosis and apoptosis. Although activated macrophages are considered to be one of the central effectors in this liver injury (15, 16), T lymphocyte infiltration is also presumed to be essential for the induction of liver damage (17–19). Indeed, during the priming phase, Th1 cells predominate in the liver in response to the synergistic action of IL-12 and IL-18 (18, 19).

It is likely that certain chemokines play roles in trafficking of effector T lymphocytes into inflamed areas of the liver. However, despite the observed massive lymphocyte infiltration, the identities of the chemokines that regulate lymphocyte infiltration and the subset of lymphocytes that act as effector cells have not been identified yet. We investigated here whether TARC was critically involved in lymphocytic infiltration into the liver and also evaluated the therapeutic efficacy

1. Abbreviations used in this paper: ALT, alanine transferase; CCR, CC chemokine receptor; CXCR, CXC chemokine receptor; FasL, Fas ligand; FHF, fulminant hepatic failure; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IP-10, IFN-γ–inducible protein; MDC, macrophage-derived chemokine; Mig, monokine induced by IFN-γ; MIP-1, macrophage inflammatory protein-1; NKT, natural killer T cell; TARC, thymus and activation-regulated chemokine.
of neutralizing anti-TARC mAb in preventing hepatic lesions in this murine model of FHF.

**Methods**

Mice. Specific pathogen-free female C57BL/6 (8-9 wk old) mice were obtained from CLEA Japan Inc. (Tokyo, Japan) and bred in a pathogen-free mouse facility of the Department of Molecular Preventive Medicine. All animal experiments complied with the standards set out in the guidelines of The University of Tokyo.

Reagents. *P. acnes* (ATCC 11828) was grown, heat killed, and lyophilized as described previously (14). LPS derived from *Escherichia coli* O55:B5 was purchased from Difco Laboratories (Detroit, MI).

mAbs. We have produced a hamster anti-mouse TARC mAb, 5H5-1-3 (Baba, M., T. Imai, and O. Yoshie, manuscript in preparation). This mAb 5H5-1-3 was used for in vivo administration and preventive therapy. We have also employed neutralizing anti-TARC mAb in preventing hepatic lesions (MDC). This mAb 5H5-1-3 was used for in vivo administration and immunohistochemical studies.

Induction of liver injury. The mice were injected with 1 mg of heat-killed *P. acnes* suspended in 100 µl of PBS via the tail vein. 7 d later, they were given an intravenous injection of 0.3 µg of LPS in 100 µl of PBS. At the indicated time interval, at least five mice were killed at each time point. Approximately 1 ml of blood was obtained by cardiac puncture under ether anesthesia and liver specimens were sampled. For the indicated experiments, 100 µg of anti-TARC mAb or hamster gamma globulin (ROCKLAND, Gilbertsville, PA) was dissolved in 100 µl of PBS. They were administered to mice intravenously 1 h before LPS challenge. Sera and liver specimens were obtained 1 or 6 h after LPS challenge. The survival rate was also determined at various time points after LPS challenge.

Histology. Liver specimens were fixed in 10% neutrally buffered formalin and were paraffin embedded. Deparaffinized sections (3 µm) were stained with hematoxylin and eosin and analyzed by light microscopy.

Immunohistochemistry. Liver specimens were fixed for 4 h at 4°C in periodate-lysine-paraformaldehyde solution, washed for 4 h with PBS containing 10, 15, and 20% sucrose, embedded in Tissue-Tek O.C.T. compound (Miles, Elkhart, IN), frozen in liquid nitrogen, and cut by a cryostat into 7-µm-thick sections. After inhibition of endogenous peroxidase activity (20), the sections were incubated with a hamster anti-mouse TARC mAb or control hamster IgG at a concentration of 10 µg/ml. They were treated sequentially with horseradish peroxidase-conjugated anti-hamster IgG (Southern Biotechnology Associates, Inc., Birmingham, AL). After visualization with 3,3'-diaminobenzidine (Wako Chemicals, Dallas, TX), slides were counterstained with Mayer’s hematoxylin.

Chemokine and cytokine gene expression analysis in liver. Total RNA was isolated from liver specimens and sorted liver infiltrating CD4+ T lymphocytes using RNAzol® (BIOTECX LAB, Houston, TX), according to the manufacturer’s instructions, and reverse transcribed into cDNA and amplified. The expressions of TARC, CCR4, CCR5, CXCR chemokine receptor 3 (CXCXR3), TNF-α, and FasL were determined by a novel method for real time quantitative PCR using the ABI 7700 sequence detector system (PE Applied Biosystems, Foster City, CA) (21). The sense primer for TARC was 5' -CATGCATGGTGAGCTGTCAAGCC-3', and the antisense primer was 5' -TTGGTGTGGCTTGACGACA-3'. The sense primer for CCR5 was 5' -AACGCTGAACCTCCCAGGC-3', and the antisense primer was 5' -CTTCCTGCTCCGTACG-3'. The sense primer for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 5' -AGATGACTCCACCTAGGC-3', and the antisense primer was 5' -TCTGGCTCTGGAAAGTGGT-3'. The reaction master mix containing a CDNA sample was prepared according to the manufacturer’s protocols to yield final concentrations of 1X PCR buffer A, 200 µM dATP, dCTP, dGTP, and 400 µM dUTP, 4 mM MgCl2, 1.25 U AmpliTaq DNA polymerase, 0.5 U Amp-Erase uracil-N-glycosylase, and 200 µM of each primer. The reactions also contained the following target hybridization probes (100 µM each). TARC probe was 5' -ATGCCATGTGTCTGCTGATGAGC-3', CCR4 probe was 5' -TATGATCAGTGTCTGGACCTG-3', CCR5 probe was 5' -TACCTGCTCAACCTGCGG-3', CXCR3 probe was 5' -ATGCCCATATCCTAGCTGTTCTGCGTGT-3', and FasL probe was 5' -AAATGGTCAAGCCTGTAGCC-3'. The samples were amplified for 50 cycles with an initial denaturation at 94°C for 2 min, followed by 1 min of annealing at 60°C, and 1 min of extension at 72°C. The PCR products were monitored by agarose gel electrophoresis.

Figure 1. Induction of TARC expression in *P. acnes*- and sequential LPS-treated liver. Real time quantitative PCR analysis of TARC mRNA expression in the liver. Total RNA was isolated from liver tissues at the following time points: untreated, 3, 5, and 7 d after *P. acnes* treatment; 2, 4, and 6 h after sequential LPS injection; or 6 h after LPS injection without *P. acnes* priming. Total RNA was reverse transcribed with or without reverse transcriptase and amplified by real time quantitative PCR for TARC and GAPDH, according to the manufacturer’s instructions. The amount of TARC was normalized to the level of GAPDH at each time point. A normalized TARC value was considered relative to the calibrator. The samples reverse transcribed without reverse transcriptase were never amplified, indicating the specificity of the PCR (data not shown). This result represents five independent experiments. PCR was performed in triplicate for each experiment.
GCCGAGAAT-3'. The probe was labeled with a reporter fluorescent dye, FAM (6-carboxyfluorescein), at the 5' end. The thermal cycling conditions included 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of amplification at 95°C for 15 s, and 55°C for 1.5 min for denaturing, anneal-extension, respectively. The PCR products were also examined by 1.8% agarose gel electrophoresis. After ethidium bromide staining, bands were visible only at the expected molecular weights for each target mRNA product.

Preparation of liver infiltrating leukocytes, flow cytometric immunofluorescence analysis, and cell sorting. Liver-infiltrating leukocytes were prepared as described by Abo and co-workers (22), with some modifications. In brief, livers taken from six mice were minced, pressed through the stainless steel mesh, and suspended in 10% FCS-DMEM. The cell suspension was treated with 33% Percoll containing 100 U/ml heparin and centrifuged at 2,000 rpm for 10 min to remove liver parenchymal cells. The pellet was treated with an RBC lysis solution, then washed three times in DMEM and resuspended in 10% FCS-DMEM.

Flow cytometric immunofluorescence analyses of liver-infiltrating cells were performed as described previously (23). In brief, 4 × 10^5 cells were incubated with a PE-labeled anti-CD4 mAb and FITC-conjugated anti-CD8 at 4°C for 30 min followed by two washes with 0.02% azide/2.5% FCS-PBS solution. The natural killer T cells (NKT) were stained with FITC-conjugated anti–mouse CD3 mAb and biotinylated anti–mouse NK1.1 revealed by PE-conjugated streptavidin. All the mAbs and reagents used for immunostaining were obtained from PharMingen (San Diego, CA) unless otherwise indicated. The instrument compensation was set in each experiment using single-color stained samples and CD4+ T cells were sorted as

![Figure 2.](image)
described previously by an EPICS Elite cell sorter (Coulter Corp., Hialeah, FL).

Cytokine production by liver CD4+ T cells in vitro. Sorted liver CD4+ T lymphocytes (10^5/well per 200 µl) were incubated in 96-well plates for 24 h with medium, coated anti-CD3 mAb (20 µg/ml), or PMA (50 ng/ml) and ionomycin (500 ng/ml). The levels of IFN-γ and IL-4 in each culture supernatant were measured by ELISA kits (Endogen, Cambridge, MA). The detection limits of the assay for IFN-γ and IL-4 were 15 and 5 pg/ml, respectively.

**Determination of serum aminotransferase.** Serum alanine transaminase (ALT) levels were determined with a Fuji DRI-CHEM 5500V (Fuji Medical System, Tokyo, Japan) according to the manufacturer’s instructions.

**Statistical analysis.** Results are expressed as the mean±SD. Statistical significance analyses were performed unless otherwise indicated by two-way ANOVA and multiple comparison methods by Scheffe. P < 0.05 was accepted as statistically significant.

## Results

**Production of TARC by granulomas during systemic inflammatory responses.** TARC mRNA was not detectable in the untreated liver, the *P. acnes*-treated liver, or the liver after the injection of a low dose of LPS into unprimed mice. However, TARC mRNA was detectable in the *P. acnes*-primed liver at 2 h after LPS challenge, and the expression levels were subsequently enhanced (Fig. 1).

To confirm the production of TARC protein and to identify the producing cells in the liver, immunohistochemical staining was performed next. There were no cells expressing TARC in the liver from either untreated (data not shown) or *P. acnes*-primed mice (Fig. 2A, panel a). In contrast, TARC was detected by anti-TARC mAb both in the granulomatous and portal areas of *P. acnes*- and LPS-treated liver (Fig. 2A, panels b and c). TARC protein was detected mainly in the cytoplasm and on the surface of macrophage-like mononuclear cells present in granulomas (Fig. 2A, panel d) and portal tract. The control Ab did not stain the same tissue, indicating the specificity of the reaction (data not shown).

**Anti-TARC mAb protects the mice from acute lethal liver injury.** To establish the biological role of TARC in causing liver injury, a neutralizing anti-TARC mAb was administered 1 h before LPS challenge. When the mice were treated with control Ab, ~ 60% of *P. acnes*-primed mice (n = 28) died in response to subsequent LPS administration within 6 h, and > 90% of the mice died within 12 h (Fig. 3A). In contrast, intravenous administration of anti-TARC mAb provided significant protection against lethality (Fig. 3A), and > 60% of the mice (n = 28) survived for 48 h.

Moreover, at 6 h after subsequent LPS challenge, multilobular hepatic injury was observed in livers from *P. acnes*-primed mice, accompanied by a marked elevation of serum ALT levels. In contrast, treatment with anti-TARC mAb

---

**Figure 3.** Protective effect of anti-TARC mAb on acute lethal liver injury. (A) Survival of mice in acute lethal liver injury induced by *P. acnes* and LPS. Anti-TARC mAb (dashed line) or control Ab (solid line) was injected as described in Methods. A generalized Wilcoxon test of Kaplan-Meier curves was used to evaluate statistical significance of survival rates. (B) Effect of anti-TARC mAb on serum ALT levels. The serum ALT levels of untreated mice, *P. acnes*-primed mice (dotted bars), and *P. acnes*-primed mice injected with LPS at 1 and 6 h were determined as described in Methods. Data represent the mean±SD from six mice. Differences between anti-TARC mAb–treated mice (closed bars) and control Ab–treated mice (open bars) are significant, *P < 0.05. (C) Real time quantitative PCR analysis of FasL mRNA and TNF-α mRNA expression in the liver. Total RNA was isolated from liver tissues at the following time points: untreated, 7 d after *P. acnes* treatment (dotted bars), and 5 or 6 h after sequential LPS injection (with control Ab, open bars, or anti-TARC mAb, closed bars). This pattern is representative of the results obtained from three independent experiments. Statistical significance with P < 0.05 is indicated by asterisks.
caused a marked reduction of serum ALT levels compared with control Ab treatment (Fig. 3 B).

Because both TNF and Fasl systems have been presumed to be involved in the process of hepatocellular damage during the eliciting phase (14–16), TNF-α mRNA and FasL mRNA expressions in the liver were analyzed by real time quantitative PCR. Neither TNF-α mRNA nor FasL mRNA was expressed in untreated or P. acnes–primed liver, but was highly induced by LPS injection after 5 and 6 h, respectively. Anti-TARC treatment significantly reduced TNF-α mRNA and FasL mRNA expressions in the liver after LPS challenge compared with control Ab treatment (Fig. 3 C).

**Anti-TARC mAb inhibits LPS-induced mononuclear cell infiltration and multilobular necrosis in the P. acnes–primed liver.** Histological examination also supported the protective effect of anti-TARC mAb. Mononuclear cells infiltrated into the hepatic lobes and formed numerous granulomas at 7 d after P. acnes treatment. Diffuse infiltration of mononuclear cells, mainly lymphocytes both in the granulomatous and portal areas, appeared after LPS challenge, culminating in multilobular coagulative necrosis and hepatocyte apoptosis (14). In contrast, at 6 h after LPS challenge, intravenous administration of anti-TARC mAb significantly blocked the increase in lymphocyte infiltration both in granulomatous and portal areas (Fig. 2 B, panel a), whereas the control Ab did not (Fig. 2 B, panel b). Moreover, anti-TARC mAb reduced the liver necrosis in spite of the preexistence of granuloma (Fig. 2 B, panel d), whereas the control Ab had no effect (Fig. 2 B, panel c). These results suggested that anti-TARC mAb reduced liver injury by inhibiting lymphocyte trafficking to liver, especially to the granulomatous areas.

**Anti-TARC mAb reduces LPS-induced CD4+ T cell infiltration into the P. acnes–primed liver.** To identify liver-infiltrating mononuclear cells, we isolated liver leukocytes, counted the cells, and performed a flow cytometric analysis. P. acnes treatment increased the leukocyte number from 1.4 × 10^6/liver to 9.5 × 10^6/liver, and subsequent LPS challenge further increased the number of infiltrating cells to 12.2 × 10^6/liver by 6 h after treatment (Fig. 4 A). We analyzed cell surface expression of CD3, CD4, CD8, and NK1.1 using a flowcytometer. Intrahepatic infiltrates consisted predominantly of CD4+ T cells. The absolute number of CD4+ T cells increased time dependently from 0.36 × 10^6/liver to 4.9 × 10^6/liver at 7 d after P. acnes treatment, and 8.1 × 10^6/liver at 6 h after LPS challenge (Fig. 4 A).

To elucidate whether anti-TARC mAb inhibited the T lymphocyte infiltration in the liver, we also determined the absolute number of liver-infiltrating T lymphocytes obtained from anti-TARC–treated liver. By 6 h after LPS challenge, anti-TARC mAb treatment markedly diminished the total number of liver leukocytes (6.2 × 10^6/liver) as well as the absolute number of CD4+ T cells (3.6 × 10^6/liver). It is noteworthy that during the LPS-induced eliciting phase the number of CD4+ T cells in anti-TARC mAb treated liver was almost

**Figure 4.** Effect of anti-TARC mAb on intrahepatic diffuse infiltration of mononuclear cells. (A) The absolute number of CD4+ (hatched bars), CD8+ (closed bars), and NKT cells (open bars) was determined by multiplying the total leukocyte number (dotted bars) by the fraction of CD4+, CD8+, and NK1.1+CD3+ population. Liver infiltrating leukocytes were prepared from untreated, P. acnes–primed, and sequentially LPS-treated mice. (B–D) Effect of anti-TARC on liver-infiltrating CD4+ T (B), NKT (C), and CD8+ T (D) cells. Liver-infiltrating CD4+ T, NKT, and CD8+ T cells were prepared from untreated, P. acnes–primed (dotted bars) and P. acnes–primed mice injected with LPS at 1 and 6 h (with control Ab, open bars, or anti-TARC mAb, closed bars). The mean ± SD of six mice are shown here. Five independent experiments were performed. Statistical significance with P < 0.05 is indicated by asterisks.

**TARC in Fulminant Hepatitis** 1937
equivalent to that in *P. acnes*-treated liver (Fig. 4B), indicating that anti-TARC mAb could block the increase in the number of liver-infiltrating CD4^+^ T cells during the eliciting phase.

**TARC recruits CCR4-expressing CD4^+^ T cells into the liver during the elicitation phase.** To examine which subset of CD4^+^ T cells was increased during the eliciting phase, we initially analyzed CCR expression by sorted liver CD4^+^ T cells. Total amounts of RNA of liver CD4^+^ T cells were extracted immediately after sorting, and real time quantitative PCR was performed. Liver CD4^+^ T cells at 7 d after *P. acnes* administration predominantly expressed CCR5 and CXCR3 mRNA, and CCR1, -2, -6, and -7 mRNAs were barely expressed. However, the expression levels of CCR5 and CXCR3 reached a peak at 7 d after *P. acnes* treatment and decreased within 6 h after LPS injection (Fig. 5A). In contrast, CD4^+^ T cells expressed significantly more CCR4 mRNA at the eliciting phase (Fig. 5A). Furthermore, anti-TARC mAb treatment selectively reduced CCR4 mRNA expression (Fig. 5B) and had no significant effect on CCR5 mRNA expression (data not shown). These results suggest that CCR4-expressing CD4^+^ T cells migrate de novo into the liver only after elicitation by LPS and the recruitment of CCR4-expressing CD4^+^ T cells was very likely regulated by TARC.

**Anti-TARC mAb treatment decreases IL-4 production by liver-infiltrating CD4^+^ T cells.** To examine which subset of CD4^+^ T cell infiltration was diminished by anti-TARC treatment, we further analyzed IL-4 and IFN-γ production by liver-infiltrating CD4^+^ T cells. Sorted liver CD4^+^ T cells were simply cultured, stimulated with an immobilized anti-CD3 mAb, or with PMA and ionomycin for 24 h in vitro, and were tested for IL-4 and IFN-γ production. Liver CD4^+^ T cells from untreated mice produced IL-4 and a small amount of IFN-γ. In contrast, the IL-4 level was decreased and the IFN-γ level was dramatically increased by CD4^+^ T cells from *P. acnes*-primed liver (Fig. 6A), indicating that the priming by *P. acnes* was characterized by a Th1 type response. However, both IL-4 and IFN-γ levels were increased by CD4^+^ T cells isolated from the liver after elicitation by LPS (Fig. 6A), and anti-TARC treatment downregulated IL-4 production, but upregulated IFN-γ production (Fig. 6B). These results suggest that IL-4-producing CD4^+^ T cells were newly recruited into the liver at the eliciting phase, and anti-TARC treatment selectively reduced the recruitment of the IL-4--producing population.

**Anti-TARC mAb reduces FasL mRNA expression in liver-infiltrated CD4^+^ T cells, and inhibits recruitment of other potential effector cells into the liver.** To investigate whether liver-infiltrating CD4^+^ T cells were actually involved in liver damage, we further examined FasL mRNA expression by sorted CD4^+^ T cells. Liver CD4^+^ T cells expressed FasL mRNA at high levels 6 h after LPS injection, and anti-TARC mAb caused ~70% reduction in FasL mRNA expression (data not shown). Furthermore, anti-TARC mAb treatment reduced the absolute number of NKT and CD8^+^ T cells (Fig. 4, C and D), which are also potential effector cells in causing liver injury. However, CCR4 mRNA was not detected in these two populations during whole disease course (data not shown). Therefore, the reduction of NKT and CD8^+^ T cells might not be a direct effect of anti-TARC mAb. These results suggest that anti-TARC mAb can inhibit infiltration of the liver by effector T cells in both direct and indirect manners, resulting in protection from massive liver injury.

**Discussion**

We demonstrated previously that TNF receptor p55 was essential for granuloma formation and that TNF and Fas could independently induce hepatocellular apoptosis (14). However, neither the TNF-α– and FasL-expressing effector cells nor the molecules which are responsible for the migration of effector cells into the liver have been identified yet. Diffuse and massive lymphocyte infiltration was observed especially in the area of granuloma and portal tract (Fig. 2B, panels b and c, and Fig. 4A). Accumulation of lymphocytes in the area of granulomatous inflammation involves interactions between tissue-spe-
The recently identified lymphocyte-directed CC chemokine, TARC, is transiently expressed in mitogen-stimulated peripheral blood mononuclear cells, constitutively expressed at high levels in the thymus, and weakly expressed in the lung, colon, and small intestine, but not in the liver (8). However, immunohistochemical studies demonstrated that TARC protein was unexpectedly produced after LPS challenge in the P. aeruginosa–primed liver. During the eliciting phase, focal multilobular necrotic areas were observed around granulomas, and TARC was present at high levels in these granulomatous areas. TARC-positive cells were also detected in bile duct epithelial cells in the portal area and scattered in the parenchyma (Fig. 2 A). These results suggest a possibility that TARC is involved in the process of T helper lymphocyte migration into the inflamed granulomatous areas. When activated T lymphocytes arrive in the granulomatous area, they are capable of initiating and causing the hepatic damage through their interaction with macrophage-like cells and/or possibly dendritic cells as antigen-presenting cells or hepatocytes.

Accumulating evidence indicates that T lymphocytes as well as macrophages are involved in the priming phase of this liver injury model (17–19). P. aeruginosa treatment induces IFN-γ–producing Th1 cells in the liver by synergistic action of IL-12 and IL-18 (19). Although CD3+CD4+ NK1.1+ T cells are reported to produce high amounts of IFN-γ (19), our results demonstrated that P. aeruginosa–primed liver CD4+ T cells were characterized by Th1 type cells (Fig. 6 A). Th1 polarization in the liver is essential to complete the priming process and to develop subsequent severe liver injury. Moreover, we demonstrated that T lymphocytes were also involved even in the eliciting phase (Fig. 4 A). Contrary to the Th1 polarization by P. aeruginosa priming, it is complicated to describe the phenotype of LPS-induced CD4+ T cells during the eliciting phase. Although sorted liver CD4+ T cells obtained at the eliciting phase are contaminated with preexisting Th1 cells, these cells produced higher levels of both IL-4 and IFN-γ (Fig. 6 A). Anti-TARC treatment downregulated IL-4 production, whereas IFN-γ production was relatively upregulated among the sorted cells (Fig. 6 B). These results suggest that IL-4–producing Th2 but not Th1 type CD4+ T cells were relatively diminished by anti-TARC treatment. Furthermore, anti-TARC mAb reduced serum IL-4 levels while serum IFN-γ levels persisted (data not shown), supporting the notion that TARC recruited Th2 type cells at the eliciting phase.

Recent investigations have revealed that CCR5 is preferentially expressed in Th1 cells, whereas CCR3 and CCR4 are selective for Th2 cells (3, 6, 11, 12, 24). Although liver CD4+ T cells predominantly expressed CCR5 mRNA during the priming phase, the expression level of CCR5 was decreased gradually after elicitation by LPS (Fig. 5 A). Since P. aeruginosa treatment polarizes liver microenvironment toward Th1, CCR5 was presumably expressed by Th1 cells in agreement with previous reports (3, 6, 11, 12). In fact, MIP-1α, which is a ligand for CCR5, mRNA was detectable at high levels in the liver during the priming phase, and the expression levels were maintained during the eliciting phase (data not shown). On the other hand, among CXC chemokines, monokine induced by IFN-γ (Mig) and IFN-γ–inducible protein (IP-10), which are considered to be selective for activated T lymphocytes (3–5), mRNAs were also expressed at high levels in the liver during the priming phase, and the expression levels were promptly decreased after elicitation by LPS (data not shown). Furthermore, liver CD4+ T cells also expressed CXCR3 mRNA, the specific receptor for Mig and IP-10, during the priming phase, and the expression levels were also decreased gradually during the eliciting phase (Fig. 5 A). Since Mig and IP-10 are reported to be induced by IFN-γ (4), IL-12– and IL-18–induced IFN-γ potentially upregulated Mig and IP-10 after P. aeruginosa treatment, then acted on CXCR3-expressing T cells to further recruit Th1 type CD4+ T cells into the liver during the priming phase.

In contrast, liver CD4+ T cells expressed higher levels of CCR4 mRNA after elicitation by LPS (Fig. 5 A). Therefore, newly migrated CD4+ T cells arriving at the eliciting phase are...
apparently predominated by CCR4-expressing cells. Anti-TARC treatment selectively reduced CCR4 expression (Fig. 5 B). These patterns are analogous to those observed for IL-4 production by liver CD4+ T cells. Hence, CCR4 seems to be preferentially expressed in IL-4-producing Th2 type murine CD4+ T cells in vivo. Although CCR3 is reported to be selective for Th2 cells (24), liver CD4+ T cells did not express CCR3 mRNA in either the priming phase or the eliciting phase (data not shown). Moreover, eotaxin mRNA, which is a ligand for CCR3, was not detectable in the liver (data not shown).

Although the recruitment of CCR4-expressing CD4+ T cells into the liver by TARC seems to be a key phenomenon in inducing liver injury, the protective effects of anti-TARC mAb on both lethality and serum ALT levels were not complete (Fig. 3, A and B). Another recently identified CC chemokine, MDC, is also a ligand for CCR4 (10), and MDC mRNA was detected in the liver after elicitation by LPS with similar patterns as for TARC mRNA expression (data not shown). In addition, anti-TARC mAb could not completely reduce CCR4 expression in liver CD4+ T cells (Fig. 5 B), suggesting that MDC might also recruit CCR4-expressing CD4+ T cells into the liver. However, a neutralizing Ab against murine MDC has not been produced yet, hence the contribution of MDC could not be adequately established in this report.

The Fas-FasL pathway constitutes a major mechanism of T cell-mediated cytotoxicity (25), and is involved in liver injury (14, 16, 26). LPS-induced CD4+ T cells expressed high levels of FasL mRNA (data not shown), whereas P. acnes–induced CD4+ T cells did not. Therefore, FasL-expressing CD4+ T cells may act as effector cells and kill Fas-expressing hepatocytes. Since anti-TARC treatment reduced FasL expression (data not shown) in CD4+ T cells, TARC might also be involved in activation of liver CD4+ T cells. Although FasL is generally considered to be expressed on Th1 cells but not Th2 cells (27), Th2 cells are also capable of inducing apoptosis under some conditions (28). In this model, it is not easy to determine which subset of Th cells critically expresses FasL because sorted CD4+ T cells contained both Th1 and Th2 cells.

Contrary to the reduction of TNF-α mRNA expression in the liver by anti-TARC treatment (Fig. 3 C), anti-TARC mAb did not affect the serum TNF-α levels (data not shown). Thus, anti-TARC mAb has only local effects to cause liver injury. Hence, the immune interactions between TARC-producing macrophages and/or possibly dendritic cells present in granulomas and LPS-induced effector T cells may be a key factor in causing massive liver injury. Moreover, anti-TARC treatment also reduced the number of liver NKT (NK1.1+CD3ehigh population) and CD8+ T cells (Fig. 4, C and D) which are potentially effector cells (29, 30). Reduction in these populations may not be a direct effect of anti-TARC mAb because CCR4 mRNA was not detectable in NKT or CD8+ T cells. One possibility is that the reduction in these T killer cells may be dependent on sequential effects of anti-TARC mAb in reducing the recruitment of CD4+ T cells, thus diminishing the immune responses between antigen-presenting cells and Th2 type CD4+ T cells. Therefore, anti-TARC treatment reduced the number of effector cells such as FasL-expressing CD+ T cells, NKT cells, and CD8+ T cells, resulting in a marked reduction in TNF-α and FasL expression in the liver (Fig. 3 C). These results may account for the protective effect of anti-TARC mAb in this liver injury model.

Based on these observations, we summarize the role of chemokines and chemokine receptors in this bacteria-induced liver injury model in Fig. 7. Our studies clearly indicate an important role for TARC at the eliciting phase. In this model, “priming” is also an essential process preparatory to sequential exacerbation induced by LPS challenge. Indeed, liver injury can be prevented by regulating the priming responses (14–18). However, the priming process is clinically unavoidable. It is more important to minimize the impairment boosted by the secondary eliciting process. In this model, migration of Th2 type CD4+ T cells in response to TARC-producing granuloma-forming cells is a key phenomenon in causing sequential massive liver injury. In vivo administration of mAb against TARC is effective even after the priming process is completed. Our finding that anti-TARC mAb prevents the subsequent le-
that liver injury may be beneficial for development of new therapeutic approaches for human diseases, including FHF and possibly various other Th2-mediated disease processes.

Acknowledgments

We are very grateful to Drs. Joost J. Oppenheim (National Cancer Institute, Frederick, MD) and Christian Vestergaard for review before submission. We thank Prof. M. Naito and Dr. G. Hasegawa (Second Department of Pathology, Niigata University School of Medicine, Niigata, Japan) for advice on immunohistochemistry. We thank Mr. S. Fujita for animal surgical assistance.

References